Category: PharmaceuticalsSyndicate content

UPDATE: Valeant ready to raise Allergan bid to at least $200/share

October 27, 2014 by MassDevice

Valeant Pharmaceuticals says it's ready to up the ante in its hostile takeover bid for Allergan.

UPDATE: Valeant ready to raise Allergan bid to at least $200/share

Abbott to go ahead with $5.3B Mylan deal, says 3rd-quarter sales match forecasts

October 22, 2014 by MassDevice

Abbott says it will go ahead with its plan to deal its generic pharmaceuticals line to Mylan for $5.3 billion and reports 3rd-quarter sales in line with expectations.

Abbott to go ahead with $5.3B Mylan deal, says 3rd-quarter sales match forecasts

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

Valeant says may raise Allergan bid; beats on profit

October 20, 2014 by MassDevice

Valeant Pharmaceuticals says it might up the ante in its hostile takeover bid for Allergan as it reports higher-than-forecast profits for its 3rd quarter.

Valeant says may raise Allergan bid; beats on profit

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

Exclusive: Actavis plans new merger approach for Allergan - sources

October 8, 2014 by MassDevice

Actavis aims to head Valeant Pharmaceuticals off at the pass with a competing bid to acquire Allergan, people familiar with the matter tell Reuters.

Exclusive: Actavis plans new merger approach for Allergan - sources

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

Baxter biopharm spinout Baxalta's R&D is Cambridge-bound

September 30, 2014 by Alex Soule

Baxter International confirmed Cambridge, Mass., as the new R&D hub for Baxalta, the planned spinout of its biopharmaceuticals business.

Baxter biopharm spinout Baxalta's R&D is Cambridge-bound

Allergan pushes to kick Valeant, Pershing out of special shareholder meeting

September 16, 2014 by Arezu Sarvestani

Allergan is still looking to prevent Valeant Pharmaceuticals and Pershing Square from voting their shares in a December 18 shareholder meeting the company was forced to host.

Allergan cedes to shareholder meeting, but still pushes for injunction

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

Built on an AdaptiveTheme using Drupal by Michael Knapp  mknapp